Decisions from  European Medicine Agency and MHRA about AstraZeneca vaccine

The European Medicines Agency (EMA) has ruled that “blood clotting,” which is rare, should be added to the AstraZeneca vaccine’s list of side effects. In the UK, The Medicines and Healthcare Products Regulatory Authority (MHRA) has recommended that the AstraZeneca vaccine should not be given to people under the age of 30 because of the risk of “blood clots,” and that a different vaccine should be given to those in question.

The Medicines and Healthcare Products Regulatory Authority (MHRA) in the UK has proposed introducing an alternative Covid-19 vaccine instead of the AstraZeneca vaccine to people under the age of 30. Noting that the risk of blood clots, which is rare when the AstraZeneca vaccine is administered to people under the age of 30, the MHRA recommended that people aged 18-29 be given another possible alternative vaccine.

THOSE WHO HAVE RECEIVED THE FIRST DOSE WILL ALSO RECEIVE THE SECOND DOSE

MHRA has also shared that people who received the first dose of the AstraZeneca vaccine should also receive the 2nd dose of the vaccine.

Only those who experience blood clots after the first dose should not be vaccinated and people with blood disease and people at risk of clotting should first consult their doctor, the MHRA said.